- Did Prosensa hurt IPO chances by disclosing Sarepta risk?
- Market ripe for Bluebird IPO, other first-time public offerings
- Sarepta falls after-hours on FDA accelerated approval guidance
- Stockwatch: A painful walking through approval probability
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.